دورية أكاديمية
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
| العنوان: | Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. |
|---|---|
| المؤلفون: | Chen CT; Department of Oncology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan, ROC.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, ROC., Feng YH; Division of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan, ROC., Yen CJ; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC., Chen SC; Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC., Lin YT; Division of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan, ROC., Lu LC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, ROC.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, ROC.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan, ROC., Hsu CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, ROC.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, ROC.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan, ROC., Cheng AL; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, ROC.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, ROC.; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, ROC.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan, ROC., Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, ROC. yuyunshao@gmail.com.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, ROC. yuyunshao@gmail.com.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan, ROC. yuyunshao@gmail.com. |
| المصدر: | Hepatology international [Hepatol Int] 2022 Oct; Vol. 16 (5), pp. 1199-1207. Date of Electronic Publication: 2022 Aug 20. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 101304009 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-0541 (Electronic) Linking ISSN: 19360533 NLM ISO Abbreviation: Hepatol Int Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Springer |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/pathology, Antibodies, Monoclonal, Humanized ; Bevacizumab/therapeutic use ; Humans ; Prognosis ; Sorafenib |
| مستخلص: | Background: The combination of atezolizumab and bevacizumab (Atezo-Bev) has become the standard first-line therapy for patients with advanced hepatocellular carcinoma (HCC), but the prognosis and treatment pattern after its treatment failure are unclear. Methods: We reviewed the medical records of patients who failed first-line Atezo-Bev treatment for advanced HCC from January 2018 to May 2021 in four Taiwan medical centers. Post-first-line survival (PFLS) was defined as the date from the failure of Atezo-Bev treatment to the date of death or last follow-up. Results: A total of 41 patients were included in the study. All patients had Child-Pugh A liver reserve before the initiation of Atezo-Bev treatment, but the liver reserve of 6 (15%) and 7 (17%) patients deteriorated to Child-Pugh B and C, respectively, after treatment failure. The median PFLS was 5.9 months. PFLS significantly differed among patients with various liver reserves after the failure of Atezo-Bev treatment (median 9.6 vs 3.8 vs 1.2 months, for Child-Pugh A, B, and C; p < 0.001). In total, 30 (73%) patients received second-line systemic therapy, and they exhibited significantly longer PFLS (median 8.0 vs 1.8 months, p = 0.033) than patients who did not. Deteriorated liver function and not receiving second-line therapy remained associated with inferior PFLS in multivariate analysis. The most common second-line therapies were sorafenib (n = 19, 63%) and lenvatinib (n = 9, 30%), with no significant differences in efficacies. Conclusion: Receiving second-line therapy and good liver reserve were associated with favorable PFLS after the failure of first-line Atezo-Bev treatment. (© 2022. Asian Pacific Association for the Study of the Liver.) |
| References: | Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. (PMID: 10.3322/caac.21660) Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. (PMID: 10.1016/S1470-2045(08)70285-7) Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173. (PMID: 10.1016/S0140-6736(18)30207-1) Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. (PMID: 10.1056/NEJMoa0708857) Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC), Korea. Korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver 2019;13:227–299. https://doi.org/10.5009/gnl19024. (PMID: 10.5009/gnl19024) Shao YY, Wang SY, Lin SM, Diagnosis G, Systemic Therapy G. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2021;120:1051–1060. (PMID: 10.1016/j.jfma.2020.10.031) Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:238–255. (PMID: 10.1093/annonc/mdy308) Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894–1905. (PMID: 10.1056/NEJMoa1915745) Network NCC. Hepatobiliary Cancers (Ver 5.2021). 2021. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf . Accessed 20 Nov 2021. Shao YY, Wu CH, Lu LC, Chan SY, Ma YY, Yen FC, Hsu CH, et al. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J Hepatol. 2014;60:313–318. (PMID: 10.1016/j.jhep.2013.08.027) Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379:54–63. (PMID: 10.1056/NEJMoa1717002) Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66. (PMID: 10.1016/S0140-6736(16)32453-9) Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind. Phase III Trial J Clin Oncol. 2020;38:193–202. (PMID: 31790344) Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020;6:e204564. (PMID: 10.1001/jamaoncol.2020.4564) Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–296. (PMID: 10.1016/S1470-2045(18)30937-9) Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, Shim JH, et al. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. Liver Cancer. 2021;10:107–114. (PMID: 10.1159/000512781) Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T, Hirooka Y, et al. Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatol Res. 2019;49:1054–1065. (PMID: 10.1111/hepr.13358) Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009;27:1800–1805. (PMID: 10.1200/JCO.2008.20.0931) Chen S-C, Chao Y, Chen MH. Lenvatinib for the treatment of HCC: a single institute experience. J Clin Oncol. 2019;37:e15611. (PMID: 10.1200/JCO.2019.37.15_suppl.e15611) Kudo M, Matilla A, Santoro A, Melero I, Gracian AC, Acosta-Rivera M, Choo SP, et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. J Clin Oncol. 2019;37:327. (PMID: 10.1200/JCO.2019.37.4_suppl.327) El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim T-Y, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. The Lancet. 2017;389:2492–2502. (PMID: 10.1016/S0140-6736(17)31046-2) Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo B-Y, Meng Z, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. J Clin Oncol. 2022;40:383. (PMID: 10.1200/JCO.2022.40.4_suppl.383) Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, Sukeepaisarnjaroen W, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40:379. (PMID: 10.1200/JCO.2022.40.4_suppl.379) Kelley RK, Yau T, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan S, et al. VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial. Ann Oncol. 2022;33:114–116. (PMID: 10.1016/j.annonc.2021.10.008) Tovoli F, Dadduzio V, De Lorenzo S, Rimassa L, Masi G, Iavarone M, Marra F, et al. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer. 2021;10:370–379. (PMID: 10.1159/000515551) Finn RS, Yau T, Hsu C-H, Toni END, Goyal L, Galle PR, Qin S, et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2. J Clin Oncol. 2022;40:423. (PMID: 10.1200/JCO.2022.40.4_suppl.423) Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, et al. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol. 2021;14:17562848211016959. (PMID: 10.1177/17562848211016959) Komatsu S, Yano Y, Fujishima Y, Ishida J, Kido M, Kuramitsu K, Yamamoto A, et al. Current role of atezolizumab plus bevacizumab therapy in the sequential treatment of unresectable hepatocellular carcinoma. Anticancer Res. 2022;42:1403–1412. (PMID: 10.21873/anticanres.15610) |
| معلومات مُعتمدة: | MOST-104-2314-B-002 -073 Ministry of Science and Technology; MOST-105-2314-B-002-194 Ministry of Science and Technology; MOST-108-2314-B-002-072-MY3 Ministry of Science and Technology; NTUH. 105-S2954 National Taiwan University Hospital; NTUH. 108-S4150 National Taiwan University Hospital; 111-HCH020 National Taiwan University Hospital Hsinchu Branch |
| فهرسة مساهمة: | Keywords: Albumin-Bilirubin (ALBI) grade; Cancer of the Liver Italian Program (CLIP) score; Child–Pugh classification; Failure of Atezo-Bev treatment; Hepatocellular carcinoma; Liver function reserve; Prognosis; Second-line therapy; Systemic therapy; Treatment pattern |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 2S9ZZM9Q9V (Bevacizumab) 52CMI0WC3Y (atezolizumab) 9ZOQ3TZI87 (Sorafenib) |
| تواريخ الأحداث: | Date Created: 20220820 Date Completed: 20221004 Latest Revision: 20221004 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1007/s12072-022-10392-x |
| PMID: | 35986846 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1936-0541 |
|---|---|
| DOI: | 10.1007/s12072-022-10392-x |